APA (7th ed.) Citation

Bogman, K., Brumm, J., Hofmann, C., Giraudon, M., Niggli, M., Sturm-Pellanda, C., . . . Schmitt, C. (2019). Assessment of Drug–Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials. Clinical pharmacokinetics, 58(9), 1205-1214. https://doi.org/10.1007/s40262-019-00757-1

Chicago Style (17th ed.) Citation

Bogman, Katrijn, et al. "Assessment of Drug–Drug Interactions Between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials." Clinical Pharmacokinetics 58, no. 9 (2019): 1205-1214. https://doi.org/10.1007/s40262-019-00757-1.

MLA (9th ed.) Citation

Bogman, Katrijn, et al. "Assessment of Drug–Drug Interactions Between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials." Clinical Pharmacokinetics, vol. 58, no. 9, 2019, pp. 1205-1214, https://doi.org/10.1007/s40262-019-00757-1.